홈 › 급성 골수성 백혈병 › 노스캐롤라이나 › Durham
NC Durham의 급성 골수성 백혈병 임상 시험
급성 골수성 백혈병 관련 연구 33개가 Durham 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
피험자 모집 중관찰 연구건강한 지원자 환영
- Durham VA Medical Center, Durham
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Duke University Medical Center, Durham
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
피험자 모집 중2상
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10마일 거리
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Duke University Medical Center, Durham
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Duke University Medical Center, Durham
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Duke University Medical Center, Durham
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
피험자 모집 중3상
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10마일 거리
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
피험자 모집 중1/2상
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
피험자 모집 중1상
- University of North Carolina at Chapel Hill, Chapel Hill · 10마일 거리
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
피험자 모집 중1/2상
- UNC School of Medicine, Division of Hematology, Chapel Hill · 10마일 거리
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
피험자 모집 중3상
- US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill · 10마일 거리
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
피험자 모집 중1상
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10마일 거리
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
피험자 모집 중1/2상
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10마일 거리
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
피험자 모집 중3상
- Duke University Medical Center, Durham
- University of North Carolina, Chapel Hill, Chapel Hill · 10마일 거리
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
피험자 모집 중1상
- University of North Carolina at Chapel Hill, Chapel Hill · 10마일 거리
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
피험자 모집 중1/2상
- Research Site, Durham
- Research Site, Chapel Hill · 10마일 거리
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
피험자 모집 중2상
- University of North Carolina at Chapel Hill, Chapel Hill · 10마일 거리
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
피험자 모집 중관찰 연구
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10마일 거리
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
피험자 모집 중
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill · 10마일 거리
Registry of Older Patients With Cancer
피험자 모집 중관찰 연구
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10마일 거리
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
피험자 모집 중2상
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10마일 거리
A Study of Revumenib and Mezigdomide in People With Leukemia
피험자 모집 중1/2상
- University of North Carolina (Data Collection Only), Chapel Hill · 10마일 거리
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
피험자 모집 중1상
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10마일 거리
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
피험자 모집 중1상
- University of North Carolina, Chapel Hill · 10마일 거리
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
피험자 모집 중2/3상
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
피험자 모집 중1/2상
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10마일 거리
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
피험자 모집 중2상
- University of North Carolina, Chapel Hill · 10마일 거리
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
피험자 모집 중1상
- Duke Blood Cancer Center, Durham
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
피험자 모집 중1상
- Duke Cancer Center, Durham
Novel Digital Application for Patients With Acute Leukemia
피험자 모집 중
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
피험자 모집 중관찰 연구
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10마일 거리
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
피험자 모집 중1/2상
- Duke University Medical Center, Durham
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
피험자 모집 중건강한 지원자 환영
- Duke University, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10마일 거리
다른 도시의 급성 골수성 백혈병 시험
- Houston, TX연구 85개
- New York City, NY연구 51개
- Boston, MA연구 44개
- Baldwin Park, CA연구 40개
- Seattle, WA연구 40개
- Columbus, OH연구 35개
- Philadelphia, PA연구 34개
- Atlanta, GA연구 30개
- Tampa, FL연구 29개
- Chicago, IL연구 26개
- Portland, OR연구 25개
- Miami, FL연구 24개
Durham의 다른 연구
- 유방암연구 63개
- 암 (전체)연구 58개
- 비소세포폐암연구 39개
- 다발성 골수종연구 37개
- 전이성 암연구 33개
- 폐암연구 32개
- 전립선암연구 32개
- 대장직장암연구 28개
- 만성 림프구성 백혈병연구 27개
- 난소암연구 27개
- 심부전연구 26개
- 췌장암연구 24개
ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.